Stock REPL REPLIMUNE GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Replimune Group, Inc.

Equities

REPL

US76029N1063

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
6.42 USD +4.39% Intraday chart for Replimune Group, Inc. -0.47% -23.84%
Apr. 08 Replimune Group Provides Interim Results for Skin Cancer Therapy MT
Mar. 26 Replimune Group, Inc. Announces Management Changes CI

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Number of employees: 284

Managers

Managers TitleAgeSince
Sushil Patel CEO
 Chief Executive Officer 53 21-05-02
Colin Love FOU
 Founder 66 15-02-28
Philip Astley-Sparke FOU
 Founder 52 15-02-28
Robert Coffin FOU
 Founder 59 15-02-28
Emily Hill DFI
 Director of Finance/CFO 44 23-09-18
Konstantinos Xynos CTO
 Chief Tech/Sci/R&D Officer 58 22-11-30
Andrew Schwendenman AUD
 Comptroller/Controller/Auditor 48 20-07-31
Christopher Sarchi PRN
 Corporate Officer/Principal 56 23-01-02

Members of the board

Members of the board TitleAgeSince
Paolo Pucci BRD
 Director/Board Member 63 20-03-31
Joseph Slattery BRD
 Director/Board Member 59 17-09-30
Robert Coffin FOU
 Founder 59 15-02-28
Philip Astley-Sparke FOU
 Founder 52 15-02-28
Hyam Levitsky BRD
 Director/Board Member 66 18-04-30
Kapil Dhingra BRD
 Director/Board Member 64 17-06-30
Christy Oliger BRD
 Director/Board Member 54 21-11-30
Dieter Weinand BRD
 Director/Board Member 63 18-06-21
Sushil Patel CEO
 Chief Executive Officer 53 21-05-02
Veleka Peeples-Dyer BRD
 Director/Board Member 52 23-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,387,786 57,829,311 ( 94.20 %) 0 94.20 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
15.55 %
9,545,336 15.55 % 78 M $
T. Rowe Price Associates, Inc. (Investment Management)
10.67 %
6,548,930 10.67 % 54 M $
SSgA Funds Management, Inc.
10.57 %
6,486,696 10.57 % 53 M $
T. Rowe Price International Ltd.
9.528 %
5,849,251 9.528 % 48 M $
STATE STREET CORPORATION
8.327 %
5,111,521 8.327 % 42 M $
Forbion Capital Partners Management Holding BV
7.927 %
4,866,499 7.927 % 40 M $
Morgan Stanley Investment Management, Inc.
7.244 %
4,447,228 7.244 % 36 M $
BlackRock Advisors LLC
7.026 %
4,312,939 7.026 % 35 M $
Redmile Group LLC
6.296 %
3,865,258 6.296 % 32 M $
Omega Fund Management LLC
4.889 %
3,001,319 4.889 % 25 M $

Company contact information

Replimune Group, Inc.

500 Unicorn Park Drive Suite 303

01801, Woburn

+781 222 9600

http://www.replimune.com
address Replimune Group, Inc.(REPL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.42 USD
Average target price
13.56 USD
Spread / Average Target
+111.15%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
REPLIMUNE GROUP, INC. Stock Replimune Group, Inc.
-23.84% 394M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. REPL Stock
  4. Company Replimune Group, Inc.